Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

India’s CRAMS Market Set To Leap To $2.46 Billion By 2010

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - Low-cost and high-end formulation manufacturing capacity is propelling the growth of Indian contract manufacturers and the sector is poised to reach an estimated $2.46 billion by 2010. From the current level of $869 million, the contract research and manufacturing services sector will show an annual growth of 41.7 percent, according to a joint study by the Confederation of Indian Industries and the global consulting firm KPMG

You may also be interested in...



Eli Lilly Global External R&D Director Yetunde Taiwo On Partnering Plans For Discovery Research: An Interview With PharmAsia News

Yetunde Taiwo, Eli Lilly's global external R&D director, is on a global hunt for molecules that can bolster Lilly's research efforts and arm it with novel therapies. Eli Lilly spends more than $3.4 billion on research every year and prides itself on being a pioneer in collaborating with scientists to bring drugs into the market. Over the last two years, Eli Lilly struck research alliances with at least four Indian companies and has increased its activities in Asia (PharmAsia News, Oct 27, 2008). Taiwo sat down with PharmAsia News' India bureau to give a lowdown on Lilly's risk-sharing strategy to shore up its new chemical entities.

Eli Lilly Global External R&D Director Yetunde Taiwo On Partnering Plans For Discovery Research: An Interview With PharmAsia News

Yetunde Taiwo, Eli Lilly's global external R&D director, is on a global hunt for molecules that can bolster Lilly's research efforts and arm it with novel therapies. Eli Lilly spends more than $3.4 billion on research every year and prides itself on being a pioneer in collaborating with scientists to bring drugs into the market. Over the last two years, Eli Lilly struck research alliances with at least four Indian companies and has increased its activities in Asia (PharmAsia News, Oct 27, 2008). Taiwo sat down with PharmAsia News' India bureau to give a lowdown on Lilly's risk-sharing strategy to shore up its new chemical entities.

India’s Growing CRAMS Sector Faces New Challenges

NEW DELHI - With an estimated annual growth of 25 percent, the Indian contract research and manufacturing services sector is attracting global attention as untapped potential for global pharmaceutical firms, but industry experts say working with India CRAMS brings several challenges

UsernamePublicRestriction

Register

LL1134409

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel